The effect of a large regional health plan's value-based insurance design program on statin use

Medical Care

Volumn 50, Issue 11, 2012, Pages 934-939

  Frank, Matthew B ^a   Fendrick, A Mark ^b,c   He, Yulei ^d   Zbrozek, Arthur ^e   Holtz, Norma ^f   Leung, Simon ^f   Chernew, Michael E ^d  

^a HARVARD UNIVERSITY   (United States)

^b Division of General Medicine   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e ASTRAZENECA   (United Kingdom)

^f Health Alliance Medical Plans   (United States)

Author keywords

adherence; statin medications; value based insurance design

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; DRUG COST; DRUG UTILIZATION; EMPLOYER; FEMALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; VALUE BASED INSURANCE DESIGN PROGRAM;

COST SHARING; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSURANCE CARRIERS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROPENSITY SCORE; UNITED STATES;

EID: 84867715386     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0b013e31826c8630     Document Type: Article

References (17)

1. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298:61-69. (Pubitemid 47026771)
2. Newhouse JP. Reconsidering the moral hazard-risk avoidance tradeoff. Health Econ. 2006;25:1005-1014. (Pubitemid 44233715)
3. Fendrick AM, Chernew ME. Value-based insurance design: a 'clinically sensitive' approach to preserve quality and contain costs. Am J Manag Care. 2006;12:18-20. (Pubitemid 43139536)
4. Choudhry NK, Rosenthal MB, Milstein A. Assessing the evidence for value-based insurance design. Health Aff. 2010;29:1988-1994.
5. Ross SD, Allen IE, Connelly JE, et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med. 1999;159:1793-1802. (Pubitemid 29379144)
6. Maciejewski ML, Farley JF, Parker J, et al. Copayment reductions generate greater medication adherence in target patients. Health Aff. 2010;29:2002-2008.
7. Chernew ME, Shah MR, Wegh A, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff. 2008;27:103-112. (Pubitemid 351198595)
8. Choudhry NK, Fischer MA, Avorn J, et al. At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff. 2010;29:1995-2001.
9. Gibson TB, Wang S, Kelly E, et al. A value-based insurance design program at a large company boosted medication adherence for employees with chronic illnesses. Health Aff. 2011;30:109-117.
10. Gibson TB, Mahoney J, Ranghell K, et al. Value-based insurance design plus disease management increased medication use and produced savings. Health Aff. 2011;30:100-108.
11. Buntin MB, Zaslavsky AM. Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures. J Health Econ. 2004;23:525-542. (Pubitemid 38569537)
12. Ellis RP, McGuire TG. Predictability and predictiveness in health care spending. J Health Econ. 2007;26:25-48. (Pubitemid 44908722)
13. Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ. 2005;24:465-488. (Pubitemid 40461909)
14. Ai C, Norton EC. Interaction terms in logit and probit models. 2003. Econ Lett. 2003;80:123-129. (Pubitemid 36598410)
15. Rubin DB. Using propensity scores to help design observational studies: application to the tobacco litigation. Health Serv Outcomes Res Methodol. 2001;2:169-188.
16. Ringel JS, Hosek SD, Vollaard BA, et al. The Elasticity of Demand for Health Care: A Review of the Literature and Its Application to the Military Health System. Santa Monica, CA: RAND; 2002.
17. Frank RG, Salkever DS. Generic entry and the pricing of pharmaceuticals. J Econ Manag Strat. 1997;6:75-90.